Keyphrases
Randomized Phase III Trial
100%
Induction Therapy
100%
Maintenance Therapy
100%
Previously Treated
100%
Ulcerative Colitis
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Etrolizumab
100%
Placebo
41%
Remission
25%
Clinical Response
16%
Induction Period
16%
Active Ulcerative Colitis
16%
Mayo Clinic
16%
Rectal Bleeding
16%
Adverse Events
12%
Serious Adverse Events
12%
Placebo Groups
8%
No Significant Difference
8%
Anti-tumor Necrosis Factor Agents
8%
Maintenance Phase
8%
Concomitant Treatment
8%
Treatment Group
4%
Anemia
4%
Europe
4%
North America
4%
Patient Report
4%
Disease Activity
4%
Monoclonal Antibody
4%
Between-group
4%
Corticosteroids
4%
Integrin
4%
Treatment Assignment
4%
One Dose
4%
Treatment Discontinuation
4%
Treatment-related Adverse Events
4%
South America
4%
Safety Analysis
4%
Appendicitis
4%
Clinical Remission
4%
3-point
4%
Intent-to-treat
4%
Placebo-controlled Study
4%
Anal Verge
4%
Middle East
4%
Treatment Facilities
4%
Remission Status
4%
Bleeding Score
4%
Induction Studies
4%
Status Maintenance
4%
Asia-Oceania
4%
Stool Frequency
4%
Medicine and Dentistry
Randomized Controlled Trial
100%
Ulcerative Colitis
100%
Maintenance Therapy
100%
TNF Inhibitor
100%
Etrolizumab
100%
Placebo
50%
Adverse Event
29%
Rectal Bleeding
16%
Anemia
4%
Disease
4%
Disease Activity
4%
Gut
4%
Intention-to-Treat Analysis
4%
Monoclonal Antibody
4%
Group Therapy
4%
Integrin
4%
Appendicitis
4%
Immunosuppressant
4%
Placebo-Controlled Study
4%
Anal Verge
4%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Ulcerative Colitis
100%
Tumor Necrosis Factor Inhibitor
100%
Etrolizumab
100%
Placebo
50%
Remission
33%
Adverse Event
29%
Rectum Hemorrhage
16%
Disease
4%
Anemia
4%
Immunosuppressive Agent
4%
Monoclonal Antibody
4%
Integrin
4%
Appendicitis
4%
Disease Activity
4%
Placebo-Controlled Study
4%